Dual-specific T cells combine proliferation and antitumor activity
- 4 November 2002
- journal article
- research article
- Published by Springer Nature in Nature Biotechnology
- Vol. 20 (12) , 1221-1227
- https://doi.org/10.1038/nbt756
Abstract
An effective immune response against cancer requires the activation and expansion of specific T cells. Tumor antigens, however, are generally poor immunogens. To achieve expansion of tumor-reactive T cells in vivo, we used a strategy of generating dual-specific T cells that could respond to a powerful immunogen while also possessing tumor reactivity. We generated dual-specific T cells by genetic modification of alloreactive T cells with a chimeric receptor recognizing folate-binding protein, an ovarian cancer–associated antigen. Mouse dual-specific T cells responded in vitro to both allogeneic antigen and tumor cells expressing folate-binding protein, and expanded in number in vivo in response to immunization with allogeneic cells. Most importantly, the combination of dual-specific T cells and immunization had an antitumor effect in vivo. We also generated human dual-specific T cells and characterized the dual-specific nature of individual clones. Assigning the tasks of expansion and tumor reactivity to different receptors within the same lymphocyte may help to overcome the problem of poor immunogenicity of tumor antigens.Keywords
This publication has 29 references indexed in Scilit:
- Reduced Graft-Versus-Host Disease-Inducing Capacity of T Cells After Activation, Culturing, and Magnetic Cell Sorting Selection in an Allogeneic Bone Marrow Transplantation Model in RatsHuman Gene Therapy, 2002
- Generation of Gene-Modified T Cells Reactive against the Angiogenic Kinase Insert Domain-Containing Receptor (KDR) Found on Tumor VasculatureHuman Gene Therapy, 2000
- Recognition of human colon cancer by T cells transduced with a chimeric receptor geneCancer Gene Therapy, 2000
- Development and Analysis of Retroviral Vectors Expressing Human Factor VIII as a Potential Gene Therapy for Hemophilia AHuman Gene Therapy, 1995
- Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor gamma chain.The Journal of Experimental Medicine, 1993
- The Molecular Basis of AllorecognitionAnnual Review of Immunology, 1993
- Induction of peripheral tolerance to class I major histocompatibility complex (MHC) alloantigens in adult mice: transfused class I MHC-incompatible splenocytes veto clonal responses of antigen-reactive Lyt-2+ T cells.The Journal of Experimental Medicine, 1990
- Use of Tumor-Infiltrating Lymphocytes and Interleukin-2 in the Immunotherapy of Patients with Metastatic MelanomaNew England Journal of Medicine, 1988
- The molecular basis of alloreactivity in antigen-specific, major histocompatibility complex-restricted T cell clonesCell, 1987
- Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificityInternational Journal of Cancer, 1987